Background: Mild Cognitive Impairment (MCI) is a risk factor for dementia and represents a critical window of opportunity to intervene and alter the trajectory of both cognitive and functional decline. Emerging life-logging technologies has shown a tremendous potential to increase autobiographical memory. Objective: The main goal of the present study is to develop a Cognitive Training program (CT) for MCI based on life-logging captured by a Wearable Camera (WeC) recording specific autobiographical episodes for stimulating posteriorly episodic memory. The challenge is to create an application to manage this large collection of images, which can be easily retrieved as events by users in a therapeutic context as a multimodal cognitive stimulation. The investigators will conduct a quasi-experimental design with non-equivalent control group, evaluating the effectiveness of the life-logging re-experiencing program immediately and 3-month follow-up period. Methodology: The design is a pretest, posttest and follow-up design, where 30 adults with MCI were sequentially allocated to one of two conditions: intervention or control group. All subjects wore a lifelogging WeC during two weeks, and subsequently they were generated several videos with the most relevant information of each event. Subjects in the Intervention Group will attend 1-hour individual training sessions 2 times per week for 14 8 weeks. Main outcomes measures will be cognitive, functional, emotional and quality of life measures, as well as biochemical measures (BDNF). Expected results: The investigators expect the outcomes to provide preliminary evidence that autobiographical experimentation CT programs can positively impact cognitive functioning and may represent an effective strategy to improve memory and functionality in those who begun to experience cognitive decline.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Change in memory after receiving treatment
Memory was measured using the Logical Memory Test from the Wechsler Memory Scale, IV version (WMS-IV, Spanish version); the International Shopping List Task and the One Card Learning Task from the computerized neurocognitive battery Cogstate.
Time frame: after 16 sessions treatment and 3 months
Change in attention after receiving treatment
Attention was measured using the Identification Task from the computerized neurocognitive battery Cogstate and the Forward Digit Span from the Wechsler Adult Intelligence Scale, fourth edition (WAIS-IV)
Time frame: after 16 sessions treatment and 3 months
Change in working memory after receiving treatment
orking memory was measured using the One Back Task from the computerized neurocognitive battery Cogstate and the Backward Digit Span from the Wechsler Adult Intelligence Scale, fourth edition (WAIS-IV).
Time frame: after 16 sessions treatment and 3 months
Change in executive function, set-shifting after receiving treatment
Set-shifting was measured using the Colors Trails Test
Time frame: after 16 sessions treatment and 3 months
Change in executive function,verbal fluency
erbal Fluency was measured using the Controlled Oral Word Association Test, spanish adaptation, and semantic fluency test using the category Animals
Time frame: after 16 sessions treatment and 3 months
Change in executive function, inhibition after receiving treatment
Inhibition was measured using the Five Digit Test
Time frame: after 16 sessions treatment and 3 months
Change in processing speed after receiving treatment
Processing speed was measured using the Detection Task from the computerized neurocognitive battery Cogstate battery
Time frame: after 16 sessions treatment and 3 months
Change in subjective memory complaints after receiving treatment
subjective memory complaints was measured using Memory Faiures of EveryDay (MFE) Test
Time frame: after 16 sessions treatment and 3 months
Change in functional capacity after receiving treatment
Functional capacity was measured using Functional Assessment Questionnaire (FAQ) and the UCSD Performance-Based Skills Assessment (UPSA).
Time frame: after 16 sessions treatment and 3 months
Change in depression and anxiety after receiving treatment
depression and anxiety were measured using the Hospital Anxiety and Depression Scale (HADS)
Time frame: after 16 sessions treatment and 3 months
Change in quality of life
Quality of life was measured using Quality of Life-Alzheimer Disease (QoL-AD)
Time frame: after 16 sessions treatment and 3 months
Change in Neuropsychiatric symptoms
Neuropsychiatric symptoms was measured using Neuropsychiatric Inventory Questionnaire (NPI)
Time frame: after 16 sessions treatment and 3 months
Change in Caregiver Burden
Caregiver Burden was measured using the Zarit Caregiver Burden Scale
Time frame: after 16 sessions treatment and 3 months
Change in patient's self-esteem
Self-Esteem was measured using the Rosenberg Self-Esteem Scale
Time frame: after 16 sessions treatment and 3 months
Change in patient and caregiver's perception of social support
Perception of social support was measured using the Duke-UNC Functional Social Support Questionnaire
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: after 16 sessions treatment and 3 months
Change in neuroplasticiy
neuroplasticiy was measured using Brain-derived neutrophic factor (BDNF) serum levels
Time frame: after 16 sessions treatment and 3 months